Perspective Therapeutics ... (CATX)
Perspective Therapeutics Inc. (CATX) Stock Price, Analysis & Data
| Bid | 3.14 |
| Market Cap | 359.01M |
| Revenue (ttm) | 409K |
| Net Income (ttm) | -116.63M |
| Beta | 1.80 |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.83 |
| P/B (ttm) | 1.11 |
| P/S (ttm) | 877.77 |
| Earnings Date | Nov 9, 2026 |
| Ask | 3.15 |
| Volume | 677,806 |
| Avg. Volume (20D) | 1,671,056 |
| Open | 3.18 |
| Previous Close | 3.18 |
| Day's Range | 3.10 - 3.26 |
| 52-Week Range | 1.96 - 6.16 |
| Analyst | Strong Buy |
| Price Target | 13 (312.70%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CATX
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted r...
Financial Performance
In 2025, Perspective Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -103.12M, an increase of 30.07%.
Financial StatementsAnalyst Forecast
According to 14 analyst ratings, the average rating for CATX stock is "Strong Buy". The 12-month stock price forecast is 13, which is upside of 312.7% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
